BDX vs OGEN · P/E 34, rev $21.84B vs rev $37.7K
Becton Dickinson and Company (BDX) versus Oragenics Inc (OGEN) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
Oragenics Inc (OGEN) is a biotechnology company listed on US.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. Revenue was up 8.2% from 2024-09-30 to 2025-09-30. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
Latest reported OGEN revenue for 2023-12-31 was $37.7K. Net income was -$20.7M. Revenue was down 71.4% from 2022-12-31 to 2023-12-31. OGEN currently screens at market cap $2.7M.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. OGEN currently screens at market cap $2.7M.
Not investment advice. Open the BDX and OGEN stock pages for the full models.
Not investment advice.